근육유래인자 Lumican의 근감소증 치료효과 및 기전연구

Abstract

Sarcopenia, or muscle loss is an important public health problem but there have been no approved drug for its treatment. It have been well known that exercise increases the amount of muscle mass. Because muscles produce and release the variety of factors (known as muscle-derived factors or myokines), I hypothesized that myokines can increase muscle mass and can be used as therapeutic agents in the treatment of sarcopenia. In this study, Lumican expression is increased in skeletal muscle of exercised mouse and Lumican secretion is increased during myogenesis. Lumican treatment stimulated myogenic differentiation of C2C12 myoblasts and stimulated Akt-mTOR signaling. Lumican-induced myogenesis is blocked by inhibitor of Integrin 2/1 or Integrin 5/3. Also, intravenous treatment of Lumican increased skeletal muscle masses and improved muscle strength in ovariectomized mice. The present results indicate that Lumican possesses the pro-myogenic effects and a potential as a therapeutic agent against sarcopenia.